WHITEPAPER
AI in Drug Discovery: A Review of US & EU Policy Guidance
Global regulatory perspectives shaping the future of AI-driven pharmaceutical innovation.
Navigating Policy to Unlock AI’s Full Potential in Drug Discovery
Artificial intelligence is transforming drug discovery — accelerating timelines, improving accuracy, and enabling novel therapeutic development. This whitepaper reviews the latest US and EU policy guidance, including the FDA’s evolving AI/ML framework, the EU AI Act, and EMA’s recommendations, providing life sciences organizations with a roadmap for responsible and effective AI adoption.
Download the whitepaper to:
Understand how AI is reshaping the drug discovery process from molecule design to repurposing.
Learn about US regulatory initiatives, including the FDA’s AI/ML Action Plan and forthcoming guidance.
Explore the EU AI Act and EMA’s human-centric approach to AI in medicine development.
See how global AI safety initiatives are influencing healthcare innovation.
Discover how to align AI-driven R&D with ethical, legal, and compliance standards.